RxDoctor Payments Data

Rocky Readling, NP

Nurse Practitioner · Shelby, NCNPI 1326475583

Payments from drug & device makers

$443in general payments, 2019–2025

Across 23 payments — averaging $19.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$170
  • AbbVie$99
  • Amgen$58
  • Mylan Specialty L.p.$39
  • AstraZeneca$34
  • Boehringer Ingelheim$28
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$443100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$443 in reported general payments places this provider in the 65th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$40,352
Medicare patients
292
Services billed
1,146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter138$113,780
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr71$37,306
Breztri AerosphereBudesonide/Glycopyr/Formoterol37$32,799
Spiriva RespimatTiotropium Bromide44$24,585
SymbicortBudesonide/Formoterol Fumarate62$19,175
Spiriva HandihalerTiotropium Bromide14$13,440
Stiolto RespimatTiotropium Br/Olodaterol Hcl18$12,034
Bevespi AerosphereGlycopyrrolate/Formoterol Fum25$10,243
Breo ElliptaFluticasone/Vilanterol20$8,342
Incruse ElliptaUmeclidinium Bromide14$5,215
Albuterol Sulfate HfaAlbuterol Sulfate182$5,049
Roflumilast45$4,793
Ventolin HfaAlbuterol Sulfate47$3,002
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$2,266
Fluticasone Propionate55$551

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$170$164,643243 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$34$62,217124 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$28$36,61962 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Shelby

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →